<DOC>
	<DOCNO>NCT00105079</DOCNO>
	<brief_summary>This 2 arm study evaluate efficacy , safety tolerability saquinavir/ritonavir lopinavir/ritonavir combination emtricitabine/tenofovir patient human immunodeficiency virus type 1 ( HIV-1 ) infection receive prior HIV treatment . Patients randomize receive either saquinavir/ritonavir 1000/100mg oral ( po ) twice daily ( bid ) + emtricitabine/tenofovir 200/300mg po daily ( qd ) , lopinavir/ritonavir 400/100mg po bid + emtricitabine/tenofovir 200/300mg po qd . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>GEMINI Study - A Study Saquinavir/Ritonavir Treatment-Naive Patients With HIV-1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>adult patient &gt; =18 year age ; chronic HIV1 infection ; treatmentnaive ; HIV1 RNA viral load &gt; =10,000copies/mL ; woman childbearing potential must negative pregnancy test , must use reliable contraception duration study 90 day last dose study medication . female pregnant breastfeeding ; active hepatitis B infection ; previous treatment antiretroviral medication ; patient receive investigational drug within last 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>